Zacks: Analysts Expect Zynerba Pharmaceuticals Inc (ZYNE) to Announce -$0.67 EPS

Wall Street brokerages expect Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to announce ($0.67) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Zynerba Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.61). Zynerba Pharmaceuticals posted earnings per share of ($0.60) during the same quarter last year, which would suggest a negative year over year growth rate of 11.7%. The firm is expected to report its next quarterly earnings report on Monday, March 11th.

On average, analysts expect that Zynerba Pharmaceuticals will report full-year earnings of ($2.87) per share for the current fiscal year, with EPS estimates ranging from ($2.94) to ($2.79). For the next year, analysts expect that the company will post earnings of ($2.43) per share, with EPS estimates ranging from ($2.77) to ($1.84). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Thursday, November 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.23.

ZYNE has been the topic of a number of recent research reports. HC Wainwright set a $23.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 13th. Cantor Fitzgerald set a $21.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Saturday, November 17th. Finally, ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $17.75.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZYNE. Thompson Siegel & Walmsley LLC bought a new stake in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $157,000. Raymond James & Associates acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $164,000. GSA Capital Partners LLP acquired a new position in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $177,000. Zeke Capital Advisors LLC acquired a new position in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $193,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $231,000. 16.50% of the stock is currently owned by institutional investors.

NASDAQ ZYNE traded up $0.03 during trading hours on Monday, reaching $4.80. The company’s stock had a trading volume of 116,277 shares, compared to its average volume of 235,962. Zynerba Pharmaceuticals has a 52 week low of $4.50 and a 52 week high of $14.45.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Featured Article: Dollar Cost Averaging

Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply